Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 428

Sort by

Sort Order Select

Journal Articles

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling

Sina A. Beer, David A. Cairns, Charlotte Pawlyn, Amy Holroyd, Elsa Ferris, Gordon Cook, Mark Drayson, Kevin Boyd, Paula Proszek, Faith E. Davies, Ruth de Tute, Matthew Jenner, Gareth J. Morgan, Roger Owen, Michael Hubank, Richard Houlston, Graham Jackson, Martin F. Kaiser

Blood (2025) 146 (22): 2670–2680.

https://doi.org/10.1182/blood.2025029987

Published: 2025

Includes: Supplemental data

Journal Articles

A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy

Wassilis S. C. Bruins, Febe Smits, Carolien Duetz, Kaz Groen, Charlotte L. B. M. Korst, A. Vera de Jonge, Christie P. M. Verkleij, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Paola M. Homan-Weert, Pieter Sonneveld, Philippe Moreau, Jürgen Claesen, Niels W. C. J. van de Donk, Sonja Zweegman, Tuna Mutis

Blood (2025) 146 (21): 2517–2530.

https://doi.org/10.1182/blood.2025028587

Published: 2025

Includes: Supplemental data

Journal Articles

Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)

Terri L. Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J. Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius Girnius, Patrick Hagen, Emma C. Scott, Antje Hoering, Brian G. M. Durie, Robert Z. Orlowski

Blood (2025) 146 (21): 2507–2516.

https://doi.org/10.1182/blood.2024027962

Published: 2025

Journal Articles

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Joshua Rivera, Qi Yan, Saeed Daneshmandi, Romain Lannes, Eriko Katsuta, JeeEun Choi, Prashant Singh, Ahmed Belal, Ronald Alberico, Ian Lund, Megan Schaefer, Hamza Hassan, Sarah Parker, Kenneth C. Anderson, Nikhil C. Munshi, Mehmet Samur, Philip L. McCarthy, Jens Hillengass, Hemn Mohammadpour

Blood (2025) 146 (20): 2392–2405.

https://doi.org/10.1182/blood.2025028963

Published: 2025

Includes: Supplemental data

Journal Articles

A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma

Debasmita Dutta, Jiye Liu, Kenneth Wen, Arghya Ray, Alessandro Salatino, Xiangdong Liu, Annamaria Gulla, Teru Hideshima, Yan Song, Kenneth C. Anderson

Blood (2025) 146 (19): 2322–2335.

https://doi.org/10.1182/blood.2025028597

Published: 2025

Includes: Supplemental data

Journal Articles

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Blood (2025) 146 (17): 2063–2072.

https://doi.org/10.1182/blood.2025029773

Published: 2025

Includes: Supplemental data

Journal Articles

Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics

Raymond K. H. Yip, Jeremy Er, Lei Qin, Quoc Hoang Nguyen, Allan Motyer, Joel S. Rimes, Amanda Light, Ruvimbo D. Mishi, Ling Ling, Casey J. A. Anttila, Ellen Tsui, Daniela Amann-Zalcenstein, Mark R. Dowling, Kelly L. Rogers, Rory Bowden, Yunshun Chen, Simon J. Harrison, Edwin D. Hawkins

Blood (2025) 146 (15): 1837–1849.

https://doi.org/10.1182/blood.2025028896

Published: 2025

Includes: Multimedia, Supplemental data

Journal Articles

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Blood (2025) 146 (15): 1747–1758.

https://doi.org/10.1182/blood.2025028313

Published: 2025

Includes: Supplemental data

Journal Articles

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Blood (2025) 146 (14): 1677–1686.

https://doi.org/10.1182/blood.2025028330

Published: 2025

Includes: Supplemental data

Journal Articles

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Blood (2025) 146 (13): 1575–1585.

https://doi.org/10.1182/blood.2024028107

Published: 2025

Includes: Supplemental data

Journal Articles

Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails

Sinan Xiong, Jianbiao Zhou, Wee-Joo Chng

Blood (2025) 146 (13): 1550–1560.

https://doi.org/10.1182/blood.2025028403

Published: 2025

Includes: Supplemental data

Journal Articles

New prognostic systems for multiple myeloma in the context of contemporary therapies

Andrew Spencer

Blood (2025) 146 (13): 1546–1549.

https://doi.org/10.1182/blood.2024023841

Published: 2025

Journal Articles

The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma

Blood (2025) 146 (11): 1286–1299.

https://doi.org/10.1182/blood.2024026340

Published: 2025

Includes: Supplemental data

Journal Articles

Immune alterations in myeloma evolution and outcomes: quo vadis?

Madhav V. Dhodapkar, Bruno Paiva

Blood (2025) 146 (9): 1041–1050.

https://doi.org/10.1182/blood.2024026227

Published: 2025

Journal Articles

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (9): 1051–1064.

https://doi.org/10.1182/blood.2024027873

Published: 2025

Includes: Supplemental data

Journal Articles

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

Blood (2025) 146 (8): 964–970.

https://doi.org/10.1182/blood.2025029234

Published: 2025

Includes: Supplemental data

Journal Articles

Eliminating the need for sequential confirmation of response in multiple myeloma

Blood (2025) 146 (7): 802–805.

https://doi.org/10.1182/blood.2024027949

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells

Blood (2025) 146 (7): 819–833.

https://doi.org/10.1182/blood.2024025536

Published: 2025

Includes: Supplemental data

Journal Articles

Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma

Smith Giri, Binod Dhakal, Natalie S. Callander, Eva Medvedova, Kelly Godby, Bhagirathbhai R. Dholaria, Susan Bal, Gayathri Ravi, Saurabh Chhabra, Rebecca W. Silbermann, Luciano Costa

Blood (2025) 146 (6): 707–716.

https://doi.org/10.1182/blood.2024027674

Published: 2025

Includes: Supplemental data

Journal Articles

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

Blood (2025) 146 (6): 679–692.

https://doi.org/10.1182/blood.2024027620

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling

A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy

Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails

New prognostic systems for multiple myeloma in the context of contemporary therapies

The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma

Immune alterations in myeloma evolution and outcomes: quo vadis?

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

Eliminating the need for sequential confirmation of response in multiple myeloma

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells

Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only